This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Detection of Circulating Tumor DNA in Plasma: A Potential Biomarker for Esophageal Adenocarcinoma

Friday, August 23, 2019

Submitted by


Source Name: The Annals of Thoracic Surgery


Matthew Egyud, Mohamedtaki Tejani, Arjun Pennathur, James Luketich, Praveen Sridhar, Emiko Yamada, Anders Ståhlberg, Stefan Filges, Paul Krzyzanowski, Jennifer Jackson, Irina Kalatskaya, Wei Jiao, Gradon Nielsen, Zhongren Zhou, Virginia Litle, Lincoln Stein, Tony Godfrey

Egyud and colleagues evaluated plasma levels of circulating tumor (ct)DNA in patients with esophageal adenocarcinoma, ranging from stage I to stage IV. The quantity of ctDNA and likelihood of ctDNA detection was greater at later stages, suggesting that it may be challenging to use for early-stage diagnosis. However, changes in ctDNA levels were indicative of response to therapy and recurrence, and the authors conclude that they may serve as a dynamic biomarker to monitor a patient’s response to treatment.

Add comment

Log in or register to post comments